Eli Lilly
-
Eli Lilly partners with South Korea’s Rznomics in US$1.3B deal
The partnership with Rznomics strengthens Lilly’s multi-pronged approach to hearing restoration, combining both gene therapy and RNA-editing platforms.
-
Eli Lilly and Purdue University forge US$250M partnership for next-generation medicines
This partnership, Lilly-Purdue 360 Initiative, potentially the largest industry-academic alliance of its kind in the United States, aims to fast-track discoveries and bring new medicines to patients more efficiently.
-
Alchemab’s neurodegenerative antibody licensed by Eli Lilly for US$415M
Under the agreement, Alchemab will manage the initial clinical development through early Phase I trials, after which Lilly will take over later-stage development, regulatory approvals, and global commercialization.
-
Lilly expands LillyDirect to support Alzheimer’s diagnosis and care
By expanding LillyDirect, the company hopes to help patients access additional independent specialty care that can work in tandem with their existing healthcare teams.
-
-
-
-
-
-
